The Neurotechnology Industry 2007 Report: Exhibits, Tables, and Charts:
1-1: Number of Individuals Afflicted by Indication, US and Worldwide, Top 15 Indications 1-2: Global Pharmaceutical Sales by Indication, 2005 1-3: Neurotechnology Industry Taxonomy 1-4: Proportion of Patient Population Segmented by Neurotech Market Opportunity 1-5: NeuroInsights Neurotech Index Performance vs. S&P500, NASQAQ Composite, and NASDAQ Biotechnology Index
2-1: Projected Percentage Increase in Global Populations aged 65 and over, 1994-2020 2-2: Neuropharmaceutical Patent Expirations and Generic Competition, 2003-2011 2-3: Neurotechnology Patent Approvals, US, 1985-2005 2-4: Neuropharmaceutical Patent Approvals, US, 1985-2005 2-5: Neurodevice Patent Approvals, US, 1985-2005 2-6: Neurodiagnostic Patent Approvals, US, 1985-2005 2-7: Selected US Foundations with a Significant focus on Brain Research and Education 2-8: Most Generous Philanthropists for Medical and Brain Research 2-9: Global Stem Cell Policy Map
3-1: Pharmaceutical Sales in Top 13 World Markets by therapeutic class, 2001-2005 3-2: Neuropharmaceutical Markets, Worldwide Sales in 2005 3-3: Number of people Afflicted and Market Size by Type of Neuropsychiatric Disorder 3-4: Neuropharmaceutical Revenues by Indication in 2004 3-5: FDA Pharmaceutical Approval Process 3-6: Clinical Trials for Alzheimer’s disease (company, compound, phase, mechanism) 3-7: Clinical Trials for Mild Cognitive Impairment (same for all clinical trial tables) 3-8: Clinical Trials for ADHD 3-9: Clinical Trials for Sleep Disorders 3-10: Clinical Trials for Depression 3-11: Clinical Trials for Anxiety disorders 3-12: Clinical Trials for Pain 3-13: Clinical Trials for Retinal and Optic Nerve Disorders 3-14: Clinical Trials for Epilepsy 3-15: Clinical Trials for Parkinson’s disease 3-16: Clinical Trials for Schizophrenia and Psychosis 3-17: Clinical Trials for Addition and Substance Abuse 3-18: Clinical Trials for Obesity Treatment 3-19: Clinical Trials for Stroke Treatment
4-1: FDA Classification and Approval Process for Medical Devices 4-2: Neurodevice Acquisition and Investment Activity: Medtronic, Boston Scientific, J&J 4-3: Neurodevice Markets (Neuroprosthetic, Neurostimulation, Neurosurgical, Neurofeedback) 4-4: Neurostimulation Device Clinical Trials
5-1: Neurodiagnostics Markets and Annual Growth (Neuroimaging, In Vitro Diagnostics, Neuroinformatics) 5-2: FDA Approval and Insurance Reimbursement of Diagnostics 5-3: Neuroimaging Technology (CT, MRI, fMRI, PET, SPECT, EEG, MEG) 5-4: Projected Number of Pharmacogenetic Tests by Indication 2003-2013 5-5: Medical Divisions of Fortune 500 Dominate Neuroimaging Market 5-6: Alzheimer’s Disease Neuroimaging Initiative 5-7: Neuroinformatics Data Storage 5-8: Paul Allen Brain Atlas Project and IBM Blue Brain Project
6-1: Total US Venture Capital Investment, 1999-2005 6-2: US Life Science Venture Capital Investment, 1999-2005 6-3: US Neurotechnology Venture Capital Investment, 1999-2005 6-4: Neurotech as Percent of Life Science Venture Investment, 1999-2005 6-5: Top Five Neurotechnology Venture Capital Financings, 2000-2005 6-6: Top 10 Neurotech Venture Capital Firms with Investments
7-1: Neurotechnology Initial Public Offerings US, 2004-Q1 2006 7-2: Selected Neurotech M&A Activity, 2004-Q1 2006 7-3: Selected Neuropharmaceutical Research and Licensing Deals 2004-Q1 2006 7-4: Neurotech Index Companies 2006 7-2: Neurotech Index Company Fundamentals 7-3: Index Company Performance
8-1 Leading Neurotechnology Research Centers 8-2 Neurotech Research Centers and Affiliated Institutes, Funding, Recent Significant Investments, Reputation, Translation of Discoveries to Industry 8-3: UCSF 8-4: UCLA 8-5: Harvard University 8-6: Stanford University 8-7: MIT 8-8: Columbia University 8-9: Washington University 8-10: University College London 8-11: Karolinska Institute 8-12: RIKEN Brain Science Institute
9-1 NeuroInsights’ 2005 Leading Neurotech Nexus Ratings 9-2 Conclusions and Policy Recommendations